Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design

Comparative Medicine

Volumn 59, Issue 2, 2009, Pages 112-128

  Emerson, Mitchell R ^a   Gallagher, Ryan J ^b,d   Marquis, Janet G ^c   LeVine, Steven M ^b  

^a MIDWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC ENCEPHALOMYELITIS; ANIMAL BEHAVIOR; ANIMAL MODEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DISEASE ACTIVITY; DISEASE COURSE; ENVIRONMENTAL FACTOR; MAST CELL; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL LYMPHOCYTE; REGULATORY T LYMPHOCYTE; REVIEW; ANIMAL; ARTICLE; DISEASE MODEL; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOLOGY; MALE; METHODOLOGY; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZATION; REPRODUCIBILITY; TRANSGENIC MOUSE;

DRUG;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; PHARMACEUTICAL PREPARATIONS; RANDOM ALLOCATION; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX;

EID: 65549104194     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (198)

1. Al Saieg N, Luzar MJ. 2006. Etanercept-induced multiple sclerosis and transverse myelitis. J Rheumatol 33:1202-1204.
2. Amor S, Smith PA, Hart B, Baker D. 2005. Biozzi mice: of mice and human neurological diseases. J Neuroimmunol 165:1-10.
3. Aranami T, Yamamura T. 2008. Th17 cells and autoimmune encephalomyelitis (EAE/MS). Allergol Int 57:115-120.
4. Arnold DL, de Stefano N, Matthews PM, Trapp BD. 2001. N-acetylaspartate: usefulness as an indicator of viable neuronal tissue. Ann Neurol 50:823-825.
5. Bakshi R, Shaikh ZA, Janardhan V. 2000. MRI T2 shortening ('black T2') in multiple sclerosis: frequency, location, and clinical correlation. Neuroreport 11:15-21.
6. Baxter AG. 2007. The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol 7:904-912.
7. Bebarta V, Luyten D, Heard K. 2003. Emergency medicine animal research: does use of randomization and blinding affect the results? Acad Emerg Med 10:684-687.
8. Bensouda-Grimaldi L, Mulleman D, Valat JP, Autret-Leca E. 2007. Adalimumab-associated multiple sclerosis. J Rheumatol 34:239-240 [discussion, 240].
9. Bettelli E, Baeten D, Jager A, Sobel RA, Kuchroo VK. 2006. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a devic-like disease in mice. J Clin Invest 116:2393-2402.
10. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. 2006. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 441:235-238.
11. Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV, Lin CH, Hanke T, Hunig T, Kerkau T, Gold R. 2005. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 202:445-455.
12. Bischof F, Hofmann M, Schumacher TN, Vyth-Dreese FA, Weissert R, Schild H, Kruisbeek AM, Melms A. 2004. Analysis of autoreactive CD4 T cells in experimental autoimmune encephalomyelitis after primary and secondary challenge using MHC class II tetramers. J Immunol 172:2878-2884.
13. Bjartmar C, Trapp BD. 2001. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 14:271-278.
14. Bjorksten B. 2008. Environmental influences on the development of the immune system: consequences for disease outcome. Nestle Nutr Workshop Ser Pediatr Program 61:243-254.
15. Black JA, Waxman SG, Smith KJ. 2006. Remyelination of dorsal column axons by endogenous Schwann cells restores the normal pattern of Nav1.6 and Kv1.2 at nodes of Ranvier. Brain 129:1319-1329.
16. Bolton C. 2007. The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis. Inflammopharmacology 15:183-187.
17. Booss J, Esiri MM, Tourtellotte WW, Mason DY. 1983. Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J Neurol Sci 62:219-232.
18. Broom KA, Anthony DC, Blamire AM, Waters S, Styles P, Perry VH, Sibson NR. 2005. MRI reveals that early changes in cerebral blood volume precede blood-brain barrier breakdown and overt pathology in MS-like lesions in rat brain. J Cereb Blood Flow Metab 25:204-216.
19. Bruck W. 2005. Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis. J Neurol 252 Suppl 5:v10-v15.
20. Buddeberg BS, Kerschensteiner M, Merkler D, Stadelmann C, Schwab ME. 2004. Behavioral testing strategies in a localized animal model of multiple sclerosis. J Neuroimmunol 153:158-170.
21. Buxton I. 2005. Pharmacokinetics and pharmacodynamics. The dynamics of drug absorption, distribution, action, and elimination. In: Brunton L, Lazo J, Parker KL, editors. Goodman and Gilman's the pharmacological basis of therapeutics, 11th ed. New York (NY): McGraw-Hill.
22. Calabrese M, De Stefano N, Atzori M, Bernardi V, Mattisi I, Barachino L, Morra A, Rinaldi L, Romualdi C, Perini P, Battistin L, Gallo P. 2007. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 64:1416-1422.
23. + T regulatory cells. Eur J Immunol 36:671-680.
24. Chen Z, Tato CM, Muul L, Laurence A, O'Shea JJ. 2007. Distinct regulation of interleukin 17 in human T helper lymphocytes. Arthritis Rheum 56:2936-2946.
25. Comabella M, Martin R. 2007. Genomics in multiple sclerosis - current state and future directions. J Neuroimmunol 187:1-8.
26. Croxford JL, Feldmann M, Chernajovsky Y, Baker D. 2001. Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL10: a comparison of the effects of protein, adenoviral or retroviral IL10 delivery into the central nervous system. J Immunol 166:4124-4130.
27. Cudrici C, Ito T, Zafranskaia E, Weerth S, Rus V, Chen H, Niculescu F, Soloviova K, Tegla C, Gherman A, Raine CS, Shin ML, Rus H. 2008. Complement C5 regulates the expression of insulin-like growth factor binding proteins in chronic experimental allergic encephalomyelitis. J Neuroimmunol 203:94-103.
28. Dal Canto RA, Shaw MK, Nolan GP, Steinman L, Fathman CG. 1999. Local delivery of TNF by retrovirus-transduced T lymphocytes exacerbates experimental autoimmune encephalomyelitis. Clin Immunol 90:10-14.
29. de Haan A, van der Vliet MR, Hendriks JJ, Heijnen DA, Dijkstra CD. 2004. Changes in characteristics of rat skeletal muscle after experimental allergic encephalomyelitis. Muscle Nerve 29:369-375.
30. de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Cabranes A, Pryce G, Baker D, Lopez-Rodriguez M, Ramos JA. 2006. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington disease and multiple sclerosis but fails to delay/arrest the progression of different motor-related disorders. Eur Neuropsychopharmacol 16:7-18.
31. Dell RB, Holleran S, Ramakrishnan R. 2002. Sample size determination. ILAR J 43:207-213.
32. Dimitrijevic M, Laban O, von Hoersten S, Markovic BM, Jankovic BD. 1994. Neonatal sound stress and development of experimental allergic encephalomyelitis in Lewis and DA rats. Int J Neurosci 78:135-143.
33. DiPiro J, Spruill W, Wade W, Blouin R, Pruemer J. 2002. Basic pharmacokinetics. In: DiPiro J, Spruill W, Wade W, Blouin R, Pruemer J, editors. Concepts in clinical pharmacokinetics. Bethesda (MD): American Society of Health-System Pharmacists.
34. Dousset V, Brochet B, Deloire MS, Lagoarde L, Barroso B, Caille JM, Petry KG. 2006. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. Am J Neuroradiol 27:1000-1005.
35. Drayer B, Burger P, Hurwitz B, Dawson D, Cain J. 1987. Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content? Am J Roentgenol 149:357-363.
36. Drayer BP, Burger P, Hurwitz B, Dawson D, Cain J, Leong J, Herfkens R, Johnson GA. 1987. Magnetic resonance imaging in multiple sclerosis: decreased signal in thalamus and putamen. Ann Neurol 22:546-550.
37. Duquette P, Pleines J, Girard M, Charest L, Senecal-Quevillon M, Masse C. 1992. The increased susceptibility of women to multiple sclerosis. Can J Neurol Sci 19:466-471.
38. Ellmerich S, Mycko M, Takacs K, Waldner H, Wahid FN, Boyton RJ, King RH, Smith PA, Amor S, Herlihy AH, Hewitt RE, Jutton M, Price DA, Hafler DA, Kuchroo VK, Altmann DM. 2005. High incidence of spontaneous disease in an HLA-DR15 and TCR transgenic multiple sclerosis model. J Immunol 174:1938-1946.
39. Elyaman W, Kivisakk P, Reddy J, Chitnis T, Raddassi K, Imitola J, Bradshaw E, Kuchroo VK, Yagita H, Sayegh MH, Khoury SJ. 2008. Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis. Am J Pathol 173:411-422.
40. Emerson MR, Biswas S, LeVine SM. 2001. Cuprizone and piperonyl butoxide, proposed inhibitors of T-cell function, attenuate experimental allergic encephalomyelitis in SJL mice. J Neuroimmunol 119:205-213.
41. Emerson MR, LeVine SM. 2004. Experimental allergic - encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase. Brain Res 1021:140-145.
42. Emerson MR, LeVine SM. Unpublished observations.
43. Englert D, Hempel K. 1979. Decrease in motor activity - an early symptom in the course of experimental allergic encephalomyelitis (EAE). Experientia 35:1207-1208.
44. Ercolini AM, Miller SD. 2006. Mechanisms of immunopathology in murine models of central nervous system demyelinating disease. J Immunol 176:3293-3298.
45. Fallis RJ, Powers ML, Sy MS, Weiner HL. 1987. Adoptive transfer of murine chronic-relapsing autoimmune encephalomyelitis. Analysis of basic protein-reactive cells in lymphoid organs and nervous system of donor and recipient animals. J Neuroimmunol 14:205-219.
46. Fazekas F, Ropele S, Enzinger C, Seifert T, Strasser-Fuchs S. 2002. Quantitative magnetization transfer imaging of prelesional white-matter changes in multiple sclerosis. Mult Scler 8:479-484.
47. Fernandez-Martin A, Gonzalez-Rey E, Chorny A, Ganea D, Delgado M. 2006. Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur J Immunol 36:318-326.
48. Festing MF. 2002. The design and statistical analysis of animal experiments. ILAR J 43:191-193.
49. Festing MF, Altman DG. 2002. Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J 43:244-258.
50. Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G. 1998. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 43:809-814.
51. Fleming KK, Bovaird JA, Mosier MC, Emerson MR, LeVine SM, Marquis JG. 2005. Statistical analysis of data from studies on experimental autoimmune encephalomyelitis. J Neuroimmunol 170:71-84.
52. + T cell responses during experimental autoimmune encephalomyelitis. Eur J Immunol 35:76-85.
53. Forge JK, Pedchenko TV, LeVine SM. 1998. Iron deposits in the central nervous system of SJL mice with experimental allergic encephalomyelitis. Life Sci 63:2271-2284.
54. Fowler SC, Birkestrand BR, Chen R, Moss SJ, Vorontsova E, Wang G, Zarcone TJ. 2001. A force-plate actometer for quantitating rodent behaviors: illustrative data on locomotion, rotation, spatial patterning, stereotypies, and tremor. J Neurosci Methods 107:107-124.
55. Friese MA, Montalban X, Willcox N, Bell JI, Martin R, Fugger L. 2006. The value of animal models for drug development in multiple sclerosis. Brain 129:1940-1952.
56. Furlan R, Brambilla E, Ruffini F, Poliani PL, Bergami A, Marconi PC, Franciotta DM, Penna G, Comi G, Adorini L, Martino G. 2001. Intrathecal delivery of IFNγ protects C57BL/6 mice from chronicprogressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol 167:1821-1829.
57. Furlan R, Poliani PL, Marconi PC, Bergami A, Ruffini F, Adorini L, Glorioso JC, Comi G, Martino G. 2001. Central nervous system gene therapy with interleukin 4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice. Gene Ther 8:13-19.
58. Gaines Das RE. 2002. Role of ancillary variables in the design, analysis, and interpretation of animal experiments. ILAR J 43:214-222.
59. Genain CP, Hauser SL. 2001. Experimental allergic encephalomyelitis in the New World monkey Callithrix jacchus. Immunol Rev 183:159-172.
60. Gold R, Hartung HP, Toyka KV. 2000. Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 6:88-91.
61. Gold R, Linington C, Lassmann H. 2006. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129:1953-1971.
62. Gordon FL, Nguyen KB, White CA, Pender MP. 2001. Rapid entry and downregulation of T cells in the central nervous system during the reinduction of experimental autoimmune encephalomyelitis. J Neuroimmunol 112:15-27.
63. Gregory GD, Raju SS, Winandy S, Brown MA. 2006. Mast cell IL4 expression is regulated by Ikaros and influences encephalitogenic Th1 responses in EAE. J Clin Invest 116:1327-1336.
64. Grimaud J, Millar J, Thorpe JW, Moseley IF, McDonald WI, Miller DH. 1995. Signal intensity on MRI of basal ganglia in multiple sclerosis. J Neurol Neurosurg Psychiatry 59:306-308.
65. Guo B, Chang EY, Cheng G. 2008. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 118:1680-1690.
66. Hansen LA, Pender MP. 1989. Hypothermia due to an ascending impairment of shivering in hyperacute experimental allergic encephalomyelitis in the Lewis rat. J Neurol Sci 94:231-240.
67. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6:1123-1132.
68. Haselkorn JK, Loomis S. 2005. Multiple sclerosis and spasticity. Phys Med Rehabil Clin N Am 16:467-481.
69. Hauser SL, Bhan AK, Gilles F, Kemp M, Kerr C, Weiner HL. 1986. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol 19:578-587.
70. Hirata S, Matsuyoshi H, Fukuma D, Kurisaki A, Uemura Y, Nishimura Y, Senju S. 2007. Involvement of regulatory T cells in the experimental autoimmune encephalomyelitis - preventive effect of dendritic cells expressing myelin oligodendrocyte glycoprotein plus TRAIL. J Immunol 178:918-925.
71. Hofstetter HH, Shive CL, Forsthuber TG. 2002. Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J Immunol 169:117-125.
72. Hofstetter HH, Targoni OS, Karulin AY, Forsthuber TG, Tary-Lehmann M, Lehmann PV. 2005. Does the frequency and avidity spectrum of the neuroantigen-specific T cells in the blood mirror the autoimmune process in the central nervous system of mice undergoing experimental allergic encephalomyelitis? J Immunol 174:4598-4605.
73. Hofstetter HH, Toyka KV, Tary-Lehmann M, Lehmann PV. 2007. Kinetics and organ distribution of IL17-producing CD4 cells in proteolipid protein 139-151 peptide-induced experimental autoimmune encephalomyelitis of SJL mice. J Immunol 178:1372-1378.
74. Howard BR. 2002. Control of variability. ILAR J 43:194-201.
75. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J. 2001. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 194:669-676.
76. Illes Z, Stern JN, Keskin DB, Reddy J, Brosnan CF, Waldner H, Santambrogio L, Kuchroo VK, Strominger JL. 2005. Copolymer effects on microglia and T cells in the central nervous system of humanized mice. Eur J Immunol 35:3683-3693.
77. Inglese M, Ge Y, Filippi M, Falini A, Grossman RI, Gonen O. 2004. Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage 21:1825-1829.
78. Institute for Laboratory Animal Research. 2002. Experimental design and statistics in biomedical research. ILAR J 43(4):191-258.
79. + T cells in EAE mice. Proc Natl Acad Sci USA 98:6301-6306.
80. Johnson KP. 2007. Natalizumab (tysabri) treatment for relapsing multiple sclerosis. Neurologist 13:182-187.
81. Johnson PD, Besselsen DG. 2002. Practical aspects of experimental design in animal research. ILAR J 43:202-206.
82. Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, Steinman L, Robinson WH. 2006. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 12:138-143.
83. Kassiotis G, Pasparakis M, Kollias G, Probert L. 1999. TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis. Eur J Immunol 29:774-780.
84. Kerschensteiner M, Stadelmann C, Buddeberg BS, Merkler D, Bareyre FM, Anthony DC, Linington C, Bruck W, Schwab ME. 2004. Targeting experimental autoimmune encephalomyelitis lesions to a predetermined axonal tract system allows for refined behavioral testing in an animal model of multiple sclerosis. Am J Pathol 164:1455-1469.
85. Kim SJ, Jung YS, Yoon MY, Kim YC. 2007. Comparative effects of dimethylsulfoxide on metabolism and toxicity of carbon tetrachloride and dichloromethane. J Appl Toxicol 27:25-31.
86. Koch M, Mostert J, Heersema D, De Keyser J. 2007. Tremor in multiple sclerosis. J Neurol 254:133-145.
87. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y. 2006. IL17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 177:566-573.
88. Korner H, Riminton DS, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD. 1997. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med 186:1585-1590.
89. Krishnamoorthy G, Lassmann H, Wekerle H, Holz A. 2006. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest 116:2385-2392.
90. Kurtzke JF. 1993. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 6:382-427.
91. Laban O, Dimitrijevic M, von Hoersten S, Markovic BM, Jankovic BD. 1995. Experimental allergic encephalomyelitis in adult DA rats subjected to neonatal handling or gentling. Brain Res 676:133-140.
92. Laban O, Markovic BM, Dimitrijevic M, Jankovic BD. 1995. Maternal deprivation and early weaning modulate experimental allergic encephalomyelitis in the rat. Brain Behav Immun 9:9-19.
93. Lafaille JJ, Nagashima K, Katsuki M, Tonegawa S. 1994. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient antimyelin basic protein T cell receptor transgenic mice. Cell 78:399-408.
94. Lane TE, Buchmeier MJ. 1997. Murine coronavirus infection: a paradigm for virus-induced demyelinating disease. Trends Microbiol 5:9-14.
95. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ. 2005. IL23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233-240.
96. Lassmann H, Ransohoff RM. 2004. The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal. Trends Immunol 25:132-137.
97. Lehmann D, Ben-Nun A. 1992. Bacterial agents protect against autoimmune disease. I. Mice pre-exposed to Bordetella pertussis or Mycobacterium tuberculosis are highly refractory to induction of experimental autoimmune encephalomyelitis. J Autoimmun 5:675-690.
98. + dendritic cells play an important role in intravenous tolerance and the suppression of experimental autoimmune encephalomyelitis. J Immunol 181:2483-2493.
99. Li J, Ridgway W, Fathman CG, Tse HY, Shaw MK. 2007. High cell surface expression of CD4 allows distinction of CD4(+)CD25(+) antigen-specific effector T cells from CD4(+)CD25(+) regulatory T cells in murine experimental autoimmune encephalomyelitis. J Neuroimmunol 192:57-67.
100. Li S, Kim JE, Budel S, Hampton TG, Strittmatter SM. 2005. Transgenic inhibition of Nogo66 receptor function allows axonal sprouting and improved locomotion after spinal injury. Mol Cell Neurosci 29:26-39.
101. Liguori M, Marrosu MG, Pugliatti M, Giuliani F, De Robertis F, Cocco E, Zimatore GB, Livrea P, Trojano M. 2000. Age at onset in multiple sclerosis. Neurol Sci 21:S825-S829.
102. Linker RA, Kroner A, Horn T, Gold R, Maurer M, Bendszus M. 2006. Iron particle-enhanced visualization of inflammatory central nervous system lesions by high resolution: preliminary data in an animal model. Am J Neuroradiol 27:1225-1229.
103. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, Slavin AJ, Old L, Bernard CC. 1998. TNF is a potent antiinflammatory cytokine in autoimmune-mediated demyelination. Nat Med 4:78-83.
104. Lublin FD, Maurer PH, Berry RG, Tippett D. 1981. Delayed, relapsing experimental allergic encephalomyelitis in mice. J Immunol 126:819-822.
105. Lyons JA, Ramsbottom MJ, Mikesell RJ, Cross AH. 2008. B cells limit epitope spreading and reduce severity of EAE induced with PLP peptide in BALB/c mice. J Autoimmun 31:149-155.
106. Lyons JA, Ramsbottom MJ, Trotter JL, Cross AH. 2002. Identification of the encephalitogenic epitopes of CNS proteolipid protein in BALB/c mice. J Autoimmun 19:195-201.
107. Lyons JA, Zhao ML, Fritz RB. 1998. Pathogenesis of acute passive murine encephalomyelitis. I. Importance of host-derived cells as determined by kinetic analysis. J Neuroimmunol 86:92-103.
108. Mancardi G, Hart B, Roccatagliata L, Brok H, Giunti D, Bontrop R, Massacesi L, Capello E, Uccelli A. 2001. Demyelination and axonal damage in a nonhuman primate model of multiple sclerosis. J Neurol Sci 184:41-49.
109. + T regulatory cells and IL10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J Immunol 178:3447-3456.
110. Manni L, Micera A, Pistillo L, Aloe L. 1998. Neonatal handling in EAE-susceptible rats alters NGF levels and mast cell distribution in the brain. Int J Dev Neurosci 16:1-8.
111. Matsushima GK, Morell P. 2001. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11:107-116.
112. Matthews AE, Weiss SR, Paterson Y. 2002. Murine hepatitis virus: a model for virus-induced CNS demyelination. J Neurovirol 8:76-85.
113. McFarland HF, Martin R. 2007. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8:913-919.
114. McRae BL, Kennedy MK, Tan LJ, Dal Canto MC, Picha KS, Miller SD. 1992. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol 38:229-240.
115. Mendel I, Kerlero de Rosbo N, Ben-Nun A. 1995. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor Vβ expression of encephalitogenic T cells. Eur J Immunol 25:1951-1959.
116. Menge T, Lalive PH, von Budingen HC, Cree B, Hauser SL, Genain CP. 2005. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy Clin Immunol 116:453-459.
117. Metz GA, Merkler D, Dietz V, Schwab ME, Fouad K. 2000. Efficient testing of motor function in spinal-cord-injured rats. Brain Res 883:165-177.
118. Meyer AL, Benson JM, Gienapp IE, Cox KL, Whitacre CC. 1996. Suppression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. J Immunol 157:4230-4238.
119. Mitchell KM, Dotson AL, Cool KM, Chakrabarty A, Benedict SH, LeVine SM. 2007. Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis. Mult Scler 13:1118-1126.
120. Mokhtarian F, McFarlin DE, Raine CS. 1984. Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature 309:356-358.
121. Morell P, Barrett CV, Mason JL, Toews AD, Hostettler JD, Knapp GW, Matsushima GK. 1998. Gene expression in brain during cuprizone-induced demyelination and remyelination. Mol Cell Neurosci 12:220-227.
122. Muller DM, Pender MP, Greer JM. 2005. Blood-brain barrier disruption and lesion localisation in experimental autoimmune encephalomyelitis with predominant cerebellar and brainstem involvement. J Neuroimmunol 160:162-169.
123. Neema M, Stankiewicz J, Arora A, Guss ZD, Bakshi R. 2007. MRI in multiple sclerosis: what's inside the toolbox? Neurotherapeutics 4:602-617.
124. Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC. 2000. Linomide in relapsing and secondary progressive MS: Part I-trial design and clinical results. North American Linomide Investigators. Neurology 54:1726-1733.
125. + regulatory T cells in the control of experimental CNS autoimmune disease. J Neuroimmunol 193:1-11.
126. Oleszak EL, Chang JR, Friedman H, Katsetos CD, Platsoucas CD. 2004. Theiler virus infection: a model for multiple sclerosis. Clin Microbiol Rev 17:174-207.
127. Palakal M, Bright J, Sebastian T, Hartanto S. 2007. A comparative study of cells in inflammation, EAE, and MS using biomedical literature data mining. J Biomed Sci 14:67-85.
128. Pandit N. 2006. Drug absorption. In: Pandit N, editor. Introduction to the pharmaceutical sciences. Baltimore (MD): Lippincott Williams and Wilkins.
129. Panitch HS, Hirsch RL, Haley AS, Johnson KP. 1987. Exacerbations of multiple sclerosis in patients treated with γ-interferon. Lancet 329:893-895.
130. Papenfuss TL, Rogers CJ, Gienapp I, Yurrita M, McClain M, Damico N, Valo J, Song F, Whitacre CC. 2004. Sex differences in experimental autoimmune encephalomyelitis in multiple murine strains. J Neuroimmunol 150:59-69.
131. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6:1133-1141.
132. Pedchenko TV, LeVine SM. 1998. Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice. J Neuroimmunol 84:188-197.
133. Peng Y, Liu CP. 2002. Characterization of proteolipid protein-peptide-specific CD(4)(+) T cell of experimental allergic encephalomyelitis in Biozzi AB/H mice. Chin Med J (Engl) 115:521-524.
134. Penhale WJ, Young PR. 1988. The influence of the normal microbial flora on the susceptibility of rats to experimental autoimmune thyroiditis. Clin Exp Immunol 72:288-292.
135. Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, Macleod M, Mignini LE, Jayaram P, Khan KS. 2007. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 334:197.
136. Piraino PS, Yednock TA, Freedman SB, Messersmith EK, Pleiss MA, Karlik SJ. 2005. Suppression of acute experimental allergic encephalomyelitis with a small-molecule inhibitor of α4 integrin. Mult Scler 11:683-690.
137. + T cell expressed CD80 regulates central nervous system effector function and survival during experimental autoimmune encephalomyelitis. J Immunol 177:2948- 2958.
138. Pollak Y, Ovadia H, Goshen I, Gurevich R, Monsa K, Avitsur R, Yirmiya R. 2000. Behavioral aspects of experimental autoimmune encephalomyelitis. J Neuroimmunol 104:31-36.
139. Pollak Y, Ovadia H, Orion E, Weidenfeld J, Yirmiya R. 2003. The EAE-associated behavioral syndrome: I. Temporal correlation with inflammatory mediators. J Neuroimmunol 137:94-99.
140. Pollak Y, Ovadia H, Orion E, Yirmiya R. 2003. The EAE-associated behavioral syndrome. II. Modulation by anti-inflammatory treatments. J Neuroimmunol 137:100-108.
141. Ponomarev ED, Maresz K, Tan Y, Dittel BN. 2007. CNS-derived interleukin 4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J Neurosci 27:10714-10721.
142. Proescholdt MA, Jacobson S, Tresser N, Oldfield EH, Merrill MJ. 2002. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol 61:914-925.
143. Radu CG, Anderton SM, Firan M, Wraith DC, Ward ES. 2000. Detection of autoreactive T cells in H2u mice using peptide-MHC multimers. Int Immunol 12:1553-1560.
144. Raine CS, Barnett LB, Brown A, Behar T, McFarlin DE. 1980. Neuropathology of experimental allergic encephalomyelitis in inbred strains of mice. Lab Invest 43:150-157.
145. Ransohoff RM. 2006. EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis. Trends Immunol 27:167-168.
146. Ransohoff RM. 2006. A mighty mouse: building a better model of multiple sclerosis. J Clin Invest 116:2313-2316.
147. Rocca MA, Cercignani M, Iannucci G, Comi G, Filippi M. 2000. Weekly diffusion-weighted imaging of normal-appearing white matter in MS. Neurology 55:882-884.
148. Russo C, Smoker WR, Kubal W. 1997. Cortical and subcortical T2 shortening in multiple sclerosis. Am J Neuroradiol 18:124-126.
149. Saggese G, Federico G, Battini R. 1993. Topical application of 1,25-dihydroxyvitamin D3 (calcitriol) is an effective and reliable therapy to cure skin lesions in psoriatic children. Eur J Pediatr 152:389-392.
150. Sallis ES, Mazzanti CM, Mazzanti A, Pereira LA, Arroteia KF, Fustigatto R, Pelizzari C, Rodrigues A, Graca DL. 2006. OSP- Immunofluorescent remyelinating oligodendrocytes in the brain-stem of toxically-demyelinated Wistar rats. Arq Neuropsiquiatr 64:240-244.
151. Schiffenbauer J, Johnson HM, Butfiloski EJ, Wegrzyn L, Soos JM. 1993. Staphylococcal enterotoxins can reactivate experimental allergic encephalomyelitis. Proc Natl Acad Sci USA 90:8543-8546.
152. Schwid SR, Trotter JL. 2000. Lessons from linomide: a failed trial but not a failure. Neurology 54:1716-1717.
153. Seewann A, Enzinger C, Filippi M, Barkhof F, Rovira A, Gass A, Miller D, Montalban X, Thompson A, Yousry T, Tintore M, de Stefano N, Palace J, Rovaris M, Polman C, Fazekas F. 2008. MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain: a review of reported findings. J Neurol 255:1-10.
154. Selmaj K, Papierz W, Glabinski A, Kohno T. 1995. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol 56:135-141.
155. Selmaj K, Raine CS, Cross AH. 1991. Antitumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 30:694-700.
156. Shankaran M, Marino ME, Busch R, Keim C, King C, Lee J, Killion S, Awada M, Hellerstein MK. 2007. Measurement of brain microglial proliferation rates in vivo in response to neuroinflammatory stimuli: application to drug discovery. J Neurosci Res 85:2374-2384.
157. Shaw R, Festing MF, Peers I, Furlong L. 2002. Use of factorial designs to optimize animal experiments and reduce animal use. ILAR J 43:223-232.
158. Sigma-Aldrich. 2003. Material safety data sheet: dimethyl sulfoxide Hybri-Max, version 1.8.
159. Sonobe Y, Jin S, Wang J, Kawanokuchi J, Takeuchi H, Mizuno T, Suzumura A. 2007. Chronological changes of CD4(+) and CD8(+) T cell subsets in the experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis. Tohoku J Exp Med 213:329-339.
160. Sriram S, Steiner I. 2005. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 58:939-945.
161. St Clair EW. 2008. The calm after the cytokine storm: lessons from the TGN1412 trial. J Clin Invest 118:1344-1347.
162. Stanford JA, Vorontsova E, Surgener SP, Gerhardt GA, Fowler SC. 2002. Aged Fischer 344 rats exhibit altered locomotion in the absence of decreased locomotor activity: exacerbation by nomifensine. Neurosci Lett 333:195-198.
163. Steinman L. 1997. Some misconceptions about understanding autoimmunity through experiments with knockouts. J Exp Med 185:2039-2041.
164. Steinman L. 1999. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 24:511-514.
165. Steinman L, Zamvil SS. 2006. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 60:12-21.
166. Stromnes IM, Goverman JM. 2006. Passive induction of experimental allergic encephalomyelitis. Nat Protoc 1:1952-1960.
167. Suen WE, Bergman CM, Hjelmstrom P, Ruddle NH. 1997. A critical role for lymphotoxin in experimental allergic encephalomyelitis. J Exp Med 186:1233-1240.
168. Sun D, Whitaker JN, Huang Z, Liu D, Coleclough C, Wekerle H, Raine CS. 2001. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol 166:7579-7587.
169. Suryani S, Sutton I. 2007. An interferon-gamma-producing Th1 subset is the major source of IL17 in experimental autoimmune encephalitis. J Neuroimmunol 183:96-103.
170. Szalai AJ, Hu X, Adams JE, Barnum SR. 2007. Complement in experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease. Mol Immunol 44:3132-3136.
171. 't Hart BA, Blezer EL, Brok HP, Boon L, de Boer M, Bauer J, Laman JD. 2005. Treatment with chimeric anti-human CD40 antibody suppresses MRI-detectable inflammation and enlargement of pre-existing brain lesions in common marmosets affected by MOG-induced EAE. J Neuroimmunol 163:31-39.
172. 't Hart BA, Hintzen RQ, Laman JD. 2008. Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin 12/23p40 in a nonhuman primate model of multiple sclerosis. Neurodegener Dis 5:38-52.
173. Taupin V, Renno T, Bourbonniere L, Peterson AC, Rodriguez M, Owens T. 1997. Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage-microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor α in the central nervous system. Eur J Immunol 27:905-913.
174. Teunis MA, Heijnen CJ, Sluyter F, Bakker JM, Van Dam AM, Hof M, Cools AR, Kavelaars A. 2002. Maternal deprivation of rat pups increases clinical symptoms of experimental autoimmune encephalomyelitis at adult age. J Neuroimmunol 133:30-38.
175. Teuscher C, Bunn JY, Fillmore PD, Butterfield RJ, Zachary JF, Blankenhorn EP. 2004. Gender, age, and season at immunization uniquely influence the genetic control of susceptibility to histopathological lesions and clinical signs of experimental allergic encephalomyelitis: implications for the genetics of multiple sclerosis. Am J Pathol 165:1593-1602.
176. Teuscher C, Doerge RW, Fillmore PD, Blankenhorn EP. 2006. eae36, a locus on mouse chromosome 4, controls susceptibility to experimental allergic encephalomyelitis in older mice and mice immunized in the winter. Genetics 172:1147-1153.
177. Toft-Hansen H, Nuttall RK, Edwards DR, Owens T. 2004. Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J Immunol 173:5209-5218.
178. Tran EH, Kuziel WA, Owens T. 2000. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein 1α or its CCR5 receptor. Eur J Immunol 30:1410-1415.
179. Tsunoda I, Kuang LQ, Igenge IZ, Fujinami RS. 2005. Converting relapsing remitting to secondary progressive experimental allergic encephalomyelitis (EAE) by ultraviolet B irradiation. J Neuroimmunol 160:122-134.
180. Tsunoda I, Kuang LQ, Theil DJ, Fujinami RS. 2000. Antibody association with a novel model for primary progressive multiple sclerosis: induction of relapsing-remitting and progressive forms of EAE in H2s mouse strains. Brain Pathol 10:402-418.
181. Tuohy VK, Yu M, Yin L, Mathisen PM, Johnson JM, Kawczak JA. 2000. Modulation of the IL10-IL12 cytokine circuit by interferon β inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis. J Neuroimmunol 111:55-63.
182. Uccelli A, Giunti D, Capello E, Roccatagliata L, Mancardi GL. 2003. EAE in the common marmoset Callithrix jacchus. Int MS J 10:6-12.
183. Urich E, Gutcher I, Prinz M, Becher B. 2006. Autoantibody-mediated demyelination depends on complement activation but not activatory Fc-receptors. Proc Natl Acad Sci USA 103:18697-18702.
184. US Department of Health and Human Services. 2005. Guidance for industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Pharmacology and toxicology.
185. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH. 1996. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47:1531-1534.
186. Vandevelde M, Zurbriggen A. 2005. Demyelination in canine distemper virus infection: a review. Acta Neuropathol 109:56-68.
187. Villoslada P, Hauser SL, Bartke I, Unger J, Heald N, Rosenberg D, Cheung SW, Mobley WC, Fisher S, Genain CP. 2000. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med 191:1799-1806.
188. Wang J, Takeuchi H, Sonobe Y, Jin S, Mizuno T, Miyakawa S, Fujiwara M, Nakamura Y, Kato T, Muramatsu H, Muramatsu T, Suzumura A. 2008. Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population. Proc Natl Acad Sci USA 105:3915-3920.
189. Wensky AK, Furtado GC, Marcondes MC, Chen S, Manfra D, Lira SA, Zagzag D, Lafaille JJ. 2005. IFNγ determines distinct clinical outcomes in autoimmune encephalomyelitis. J Immunol 174:1416-1423.
190. Werring DJ, Brassat D, Droogan AG, Clark CA, Symms MR, Barker GJ, MacManus DG, Thompson AJ, Miller DH. 2000. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain 123:1667-1676.
191. Wiendl H, Hohlfeld R. 2002. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. Bio-Drugs 16:183-200.
192. Wiendl H, Neuhaus O, Kappos L, Hohlfeld R. 2000. [Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment] Nervenarzt 71:597-610. [Article in German]
193. Wooley CM, Sher RB, Kale A, Frankel WN, Cox GA, Seburn KL. 2005. Gait analysis detects early changes in transgenic SOD1(G93A) mice. Muscle Nerve 32:43-50.
194. Wuerfel J, Tysiak E, Prozorovski T, Smyth M, Mueller S, Schnorr J, Taupitz M, Zipp F. 2007. Mouse model mimics multiple sclerosis in the clinicoradiological paradox. Eur J Neurosci 26:190-198.
195. Xiao BG, Wu XC, Yang JS, Xu LY, Liu X, Huang YM, Bjelke B, Link H. 2004. Therapeutic potential of IFNγ-modified dendritic cells in acute and chronic experimental allergic encephalomyelitis. Int Immunol 16:13-22.
196. Yu M, Nishiyama A, Trapp BD, Tuohy VK. 1996. Interferon β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 64:91-100.
197. Yuan R, Maeda Y, Li W, Lu W, Cook S, Dowling P. 2008. Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE. PLoS ONE 3:e1924.
198. Zamvil S, Nelson P, Trotter J, Mitchell D, Knobler R, Fritz R, Steinman L. 1985. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 317:355-358.